Showing 13 to 20 of 20 results
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
Weekly Semaglutide Shows Promise in Reducing Alcohol Consumption
A JAMA Psychiatry study shows weekly semaglutide significantly reduced alcohol cravings and heavy drinking days in 48 adults with alcohol use disorder, with nearly 40% of the semaglutide group reporting no heavy drinking days in the final month versus 20% in the placebo group.
Weekly Semaglutide Shows Promise in Reducing Alcohol Consumption
A JAMA Psychiatry study shows weekly semaglutide significantly reduced alcohol cravings and heavy drinking days in 48 adults with alcohol use disorder, with nearly 40% of the semaglutide group reporting no heavy drinking days in the final month versus 20% in the placebo group.
Progress
40% Bias Score
Ozempic and Increased Risk of Blindness: New Studies Reveal Elevated NAION Risk
New studies in Denmark and Norway reveal that Ozempic, a popular diabetes medication used for weight loss, more than doubles the risk of NAION (non-arteritic anterior ischemic optic neuropathy), a severe eye disease potentially causing blindness, compared to alternative treatments; these findings co...
Ozempic and Increased Risk of Blindness: New Studies Reveal Elevated NAION Risk
New studies in Denmark and Norway reveal that Ozempic, a popular diabetes medication used for weight loss, more than doubles the risk of NAION (non-arteritic anterior ischemic optic neuropathy), a severe eye disease potentially causing blindness, compared to alternative treatments; these findings co...
Progress
52% Bias Score
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Progress
40% Bias Score
Wegovy Approved for Heart Disease Treatment in Australia
Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.
Wegovy Approved for Heart Disease Treatment in Australia
Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.
Progress
36% Bias Score
Semaglutide Shows Promise in Reducing Alcohol Consumption
A US study found that semaglutide injections reduced alcohol consumption by 41% in 48 adults with alcohol use disorder over nine weeks, suggesting a potential new treatment; however, further research is needed.
Semaglutide Shows Promise in Reducing Alcohol Consumption
A US study found that semaglutide injections reduced alcohol consumption by 41% in 48 adults with alcohol use disorder over nine weeks, suggesting a potential new treatment; however, further research is needed.
Progress
36% Bias Score
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Progress
48% Bias Score
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Progress
20% Bias Score
Showing 13 to 20 of 20 results